

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**




PLEASE STAMP AND RETURN TO SHOW RECEIPT OF:

In re Application of: Gregory M. Glenn et al.  
Application No. 09/266,803  
Filed: March 12, 1999  
Group Art Unit: 1644  
Examiner: Ewoldt, Gerald R.  
For: Adjuvant for Transcutaneous Immunization

Papers Submitted:

1. Supplemental Information Disclosure Statement
2. Form PTO 1449
3. Copy of Documents 1-2
4. Copy of Partial European Search Report dated November 17, 2003

Date: February 17, 2004  
Attorney Docket 056707-5002-03-US  
EEV:ghb



25

**DOCKETED**  
By dw Date 2/18/04



PATENT  
Attorney Docket 056707-5002-03

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: <b>Gregory M. Glenn <i>et al.</i></b>	)	
Application No. <b>09/266,803</b>	)	Group Art Unit: <b>1644</b>
Filed: <b>March 12, 1999</b>	)	Examiner: <b>Ewoldt, Gerald R.</b>
For: <b>Adjuvant for Transcutaneous Immunization</b>	)	

Commissioner for Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. § 1.97(c) and (e)(1)**

Pursuant to 37 C.F.R. § 1.56 and § 1.97(c) and (e)(1), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 form. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of any of a Final Office Action, a Notice of Allowance, or any action that otherwise closes prosecution in the application for the above-referenced application.

To the best of the undersigned's knowledge, each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. A copy of the Search report issued by the European Patent Office on November 17, 2003 is enclosed for the Examiner's consideration.

With the exception of the first cited international publication (WO 95/17211 A) which was previously submitted, copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the above-listed documents are material or constitute prior art. If the Examiner applies the

documents as prior art against any claim in the application and Applicants determine that the cited document does not constitute prior art under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the application and the references therein, should one or more of the documents be applied against the claims of the present application.


**Except** for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. § 1.16 and § 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. § 1.136(a)(3).

Dated: **February 17, 2004**  
Morgan, Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel: 202-739-3000  
Fax: 202-739-3001


Respectfully submitted,  
Morgan, Lewis & Bockius LLP



Michael S. TUSCAN Pg 16-43, 210



Erich E. Veitenheimer, III, Ph.D.  
Registration No. 40,420



<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Attorney Docket 056707-5002-03		Application No. 09/266,803	
PTO Form 1449				Filing Date: March 12, 1999		Group Art Unit: 1644	
Applicant: Gregory M. Glenn <i>et al.</i>							
Page 1 of 1							
<b>U.S. PATENT DOCUMENTS</b>							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document No.	Date	Country	Class	Sub-Class	Translation
	1	WO 8806626	09/07/1988	PCT			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	2	Krueger <i>et al.</i> (1995) The family of bacterial ADP-ribosylating exotoxins, Clin. Microbiol. Rev. 8(1):34-47, American Society for Microbiology, Washington, D.C., USA.					
Examiner				Date Considered			
<b>Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							